Regeneron beats quarterly estimates on eczema drug strength, shares rise
Reported by Yahoo Finance · finance.yahoo.com · July 30, 2026
July 30 () - Regeneron on Thursday beat Wall Street estimates for second-quarter revenue and profit, helped by strong demand for its eczema drug Dupixent and a high-dose version of its eye drug Eylea. Shares rose nearly 5% before the bell.
What the tape says
What to watch: Regeneron Pharmaceuticals Inc. (REGN) beat estimates by roughly 5% — check whether the reaction already prices in the surprise before chasing it.
Market reaction today: $REGN -0.66%
Tone and severity are deterministic keyword classification — not a prediction, a member vote, or a recommendation. Figures are extracted from the headline as published. Wook does not republish Yahoo Finance's reporting.
Your read
Discussion
No one has weighed in yet. Start the discussion on this story.
Headline and link are attributed to Yahoo Finance. Wook of Wall Street is an independent research tool and is not affiliated with Yahoo Finance. Nothing here is financial advice or a recommendation — research and educational content only.